Please login to the form below

Not currently logged in
Email:
Password:

Biovitrum

This page shows the latest Biovitrum news and features for those working in and with pharma, biotech and healthcare.

FDA clears Sobi’s Gamifant for ‘hyper-inflammation’ disease

FDA clears Sobi’s Gamifant for ‘hyper-inflammation’ disease

Approval adds to growing US portfolio. Swedish Orphan Biovitrum (Sobi) has the US approval it sought for Gamifant, an ultra-rare disease therapy it licensed from Novimmune for $452m a few

Latest news

More from news
Approximately 4 fully matching, plus 15 partially matching documents found.

Latest Intelligence

  • A rare opportunity A rare opportunity

    Orphan Biovitrum) a company that, as its name suggests, is entirely dedicated to rare conditions.

  • Deal Watch table for July 2013 Deal Watch table for July 2013

    49. †Auxilium Pharmaceuticals/ Swedish Orphan Biovitrum.  Development, supply and commercialisation. Xiapex (collagenase clostridium histolyticum) (approved)  .  40. All deals are worldwide unless otherwise noted – see below:.   .

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 2 fully matching, plus 7 partially matching documents found.

Latest from PMHub

  • Say Communications

    Roche Diabetes Care. Swedish Orphan Biovitrum. Target Ovarian Cancer. Trudell Medical.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

We're award-winning joint working specialists. We help our clients to transform healthcare through effective collaboration, and deliver work to feel...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics